Breaking News

Florida Biologix Spins-Off From University of Florida

Ampersand Capital Partners provides growth equity to expand business

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Florida Biologix, a contract development and manufacturing organization (CDMO) focused on complex biological products, has spun-off from the University of Florida (UF) with financial backing from Ampersand Capital Partners. Ampersand’s investment will be used to further expand the company’s manufacturing capabilities in the areas of gene and cell therapies. Florida Biologix was established in 2006 as a component of the UF Center of Excellence for Regenerative Health Biotechnology ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters